{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:33:30Z","timestamp":1758274410542,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous disease that is mediated by antibodies that bind collagen VII. The treatment of EBA can be challenging and the use of multiple immunomodulatory drugs is often required. Rituximab has been reported to be an effective treatment for recalcitrant EBA, although the evidence base for this treatment is limited to case reports and case series.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to evaluate the efficacy of rituximab for the treatment of patients with EBA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with EBA who were treated with rituximab were identified by searching electronic medical records. The diagnostic criteria for EBA were mechanobullous skin lesions and\/or mucosal ulceration, indirect immunofluorescence localizing to the base of salt-split skin, and positive collagen VII antibodies. Clinical disease activity, collagen VII antibody levels and serum immunoglobulin levels were recorded at each follow-up visit over a 600-day period. Treatment responses were classified as follows: complete remission (CR) was defined as the absence of new or established lesions on minimal therapy for 2\u2005months, partial remission (PR) was defined as transient lesions that heal within 1 week on minimal therapy, and active disease was defined as the development of new lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 14 patients with EBA were treated with rituximab. CR or PR was observed in 11 patients, and the duration of response varied between 4 and 24\u2005months. A reduction in collagen VII antibody levels was observed in all patients. No significant adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Rituximab is a safe and effective treatment for patients with recalcitrant EBA, although there was significant heterogeneity in the disease response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae283","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:54:19Z","timestamp":1728568459000},"page":"97-103","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-2726","authenticated-orcid":false,"given":"Sosipatros P","family":"Bratsos","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilan","family":"Demir","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B","family":"Mee","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W","family":"Groves","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Tull","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"2024122223532810700_llae283-B1","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.80.11.3168","article-title":"Isolation and partial characterization of a new human collagen with an extended triple-helical structural domain","volume":"80","author":"Bentz","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024122223532810700_llae283-B2","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1073\/pnas.88.16.6931","article-title":"Human type VII collagen: cDNA cloning and chromosomal mapping of the gene","volume":"88","author":"Parente","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024122223532810700_llae283-B3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.autrev.2019.06.007","article-title":"Epidermolysis bullosa acquisita: a comprehensive review","volume":"18","author":"Kridin","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2024122223532810700_llae283-B4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2024122223532810700_llae283-B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.det.2018.12.003","article-title":"Treatment update of autoimmune blistering diseases","volume":"37","author":"Kridin","year":"2019","journal-title":"Dermatol Clin"},{"key":"2024122223532810700_llae283-B6","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/dth.12726","article-title":"The use of rituximab in treatment of epidermolysis bullosa acquisita: three new cases and a review of the literature","volume":"31","author":"Bevans","year":"2018","journal-title":"Dermatol Ther"},{"key":"2024122223532810700_llae283-B7","first-page":"779","article-title":"Rituximab for the treatment of epidermolysis bullosa acquisita: a large case series of 15 patients","volume":"21","author":"Dasdar","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024122223532810700_llae283-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.16138","article-title":"International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita","volume":"179","author":"Prost-Squarcioni","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024122223532810700_llae283-B9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/archderm.143.2.192","article-title":"Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)","volume":"143","author":"Niedermeier","year":"2007","journal-title":"Arch Dermatol"},{"key":"2024122223532810700_llae283-B10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"2024122223532810700_llae283-B11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/pde.12006","article-title":"A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy","volume":"31","author":"McKinley","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"2024122223532810700_llae283-B12","first-page":"779","article-title":"Rituximab for the treatment of epidermolysis bullosa acquisita: a large case series of 15 patients","volume":"21","author":"Dasdar","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024122223532810700_llae283-B13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2006.07596.x","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"key":"2024122223532810700_llae283-B14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.2011.01360.x","article-title":"Successful treatment of epidermolysis bullosa acquisita with rituximab therapy","volume":"39","author":"Kim","year":"2012","journal-title":"J Dermatol"},{"key":"2024122223532810700_llae283-B15","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"2024122223532810700_llae283-B16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2024122223532810700_llae283-B17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2024122223532810700_llae283-B18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.12011","article-title":"Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study","volume":"168","author":"Marzano","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024122223532810700_llae283-B19","doi-asserted-by":"crossref","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae283\/59876026\/llae283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/97\/59876026\/llae283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/97\/59876026\/llae283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:53:36Z","timestamp":1734911616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/97\/7817383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,25]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae283","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,25]]}}}